New Steroid-Like drug tested for muscle disease

NCT ID NCT05166109

Completed Disease control Sponsor: ReveraGen BioPharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested vamorolone, a drug similar to steroids, against a placebo in 46 males with Becker muscular dystrophy. The goal was to check safety and tolerability over 24 weeks, while also looking for early signs of benefit. The study is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vamorolone
What this could lead to: If it works, vamorolone could offer a safer steroid option to help control muscle weakness in Becker muscular dystrophy.
What could go wrong: This is a small, early-phase trial focused on safety, not proof of effectiveness. The drug may not improve muscle function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BECKER MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Becker muscular dystrophy Duchenne muscular dystrophy muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BECKER MUSCULAR DYSTROPHY

Contacts and locations

Locations

Azienda Ospedale Universita Padova

Padova, 35129, Italy
University of Pittsburgh

Pittsburgh, Pennsylvania, 15261, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.